Novo Mirza, Nordén Rickard, Westin Johan, Dellgren Göran, Böhmer Jens, Ricksten Anne, Magnusson Jesper M
Department of Respiratory Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Transpl Int. 2024 Jul 24;37:12772. doi: 10.3389/ti.2024.12772. eCollection 2024.
During the last few years, cell-free DNA (cfDNA) has emerged as a possible non-invasive biomarker for prediction of complications after lung transplantation. We previously published a proof-of-concept study using a digital droplet polymerase chain reaction (ddPCR)-based method for detection of cfDNA. In the current study, we aimed to further evaluate the potential clinical usefulness of detecting chronic lung allograft dysfunction (CLAD) using three different ddPCR applications measuring and calculating the donor fraction (DF) of cfDNA as well as one method using the absolute amount of donor-derived cfDNA. We analyzed 246 serum samples collected from 26 lung transplant recipients. Nine of the patients had ongoing CLAD at some point during follow-up. All four methods showed statistically significant elevation of the measured variable in the CLAD samples compared to the non-CLAD samples. The results support the use of ddPCR-detected cfDNA as a potential biomarker for prediction of CLAD. These findings need to be validated in a subsequent prospective study.
在过去几年中，游离DNA（cfDNA）已成为一种可能用于预测肺移植术后并发症的非侵入性生物标志物。我们之前发表了一项概念验证研究，该研究使用基于数字液滴聚合酶链反应（ddPCR）的方法来检测cfDNA。在当前研究中，我们旨在进一步评估使用三种不同的ddPCR应用来测量和计算cfDNA的供体分数（DF）以及一种使用供体来源cfDNA绝对量的方法来检测慢性肺移植功能障碍（CLAD）的潜在临床实用性。我们分析了从26名肺移植受者收集的246份血清样本。其中9名患者在随访期间的某个时间点出现了持续性CLAD。与非CLAD样本相比，所有四种方法均显示CLAD样本中测量变量有统计学意义的升高。结果支持将ddPCR检测的cfDNA用作预测CLAD的潜在生物标志物。这些发现需要在后续的前瞻性研究中得到验证。
